STOCK TITAN
  1. Home
  2. News
  3. MOR

MorphoSys AG American Depositary Shares - MOR STOCK NEWS

Welcome to our dedicated page for MorphoSys American Depositary Shares news (Ticker: MOR), a resource for investors and traders seeking the latest updates and insights on MorphoSys American Depositary Shares stock.

MorphoSys AG (NASDAQ: MOR) is a premier biopharmaceutical company headquartered in Planegg, Germany, with a significant presence in Boston, Massachusetts through its subsidiary MorphoSys US Inc. Established in 1992, the company focuses on the discovery, development, and commercialization of innovative therapies for cancer and autoimmune diseases. MorphoSys has made substantial strides in biopharmaceutical research and development, positioning itself as a leader in the industry.

One of MorphoSys' key achievements is the development of Tremfya (guselkumab), which is marketed by Janssen Biotech for the treatment of plaque psoriasis. It became the first drug based on MorphoSys' antibody technology to receive regulatory approval. Another significant product is Monjuvi (tafasitamab-cxix), which received accelerated approval from the U.S. Food and Drug Administration for the treatment of a certain type of lymphoma in combination with lenalidomide.

The company's latest financial update highlights preliminary Monjuvi U.S. net product sales of $92 million for 2023, with a gross margin of 69%. MorphoSys projects 2024 Monjuvi U.S. net product sales to be between $80 and $95 million. New indications for Monjuvi are currently being explored through Phase 3 trials.

MorphoSys continues to innovate with its clinical programs, such as pelabresib (CPI-0610), an investigational treatment for myelofibrosis. Following successful Phase 3 MANIFEST-2 trial results, MorphoSys is preparing regulatory filings for 2024.

In February 2024, MorphoSys announced a Business Combination Agreement with Novartis, which includes plans for Novartis to acquire MorphoSys and obtain exclusive rights to pelabresib and tulmimetostat. Concurrently, MorphoSys will transfer all rights related to tafasitamab to Incyte Corporation.

As MorphoSys continues to advance its pipeline and optimize operations, the company remains committed to bringing more life to people living with cancer. For further information, visit MorphoSys' website and follow them on Twitter and LinkedIn.

News

MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value

Rhea-AI Summary
MorphoSys AG (MOR) has entered into a Business Combination Agreement with Novartis, who will submit a voluntary public takeover offer for all outstanding MorphoSys shares at a price of €68.00 per share in cash. Novartis also seeks exclusive, worldwide rights to develop and commercialize pelabresib and tulmimetostat. Additionally, MorphoSys entered into a Purchase Agreement to sell all rights related to tafasitamab to Incyte. The offer provides shareholders with a 94% premium to the one-month volume weighted average price before January 25, 2024. Novartis will provide resources to maximize pelabresib's potential and MorphoSys' Management Board and Supervisory Board unanimously support both agreements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.79%
Tags
acquisition
-
News

Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)

Rhea-AI Summary
Incyte has entered into an asset purchase agreement with MorphoSys AG, gaining exclusive global rights to tafasitamab, a humanized Fc-modified CD19-targeting immunotherapy marketed in the U.S. as Monjuvi® and outside of the U.S. as Minjuvi®. The new agreement allows Incyte to realize significant operating efficiencies and cost synergies. Incyte will now recognize revenue and cost for all U.S. commercialization and clinical development, and MorphoSys will no longer be eligible to receive future milestone, profit split, and royalty payments. Tafasitamab is approved in combination with lenalidomide for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and is currently in Phase 3 trials for multiple indications, including first-line DLBCL, relapsed or refractory follicular lymphoma (FL), and relapsed or refractory marginal zone lymphoma (MZL).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.79%
Tags
none
-
News

MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability

Rhea-AI Summary
MorphoSys AG reported preliminary Monjuvi U.S. net product sales of US$ 92.0 million and preliminary gross margin of 69% for 2023. Anticipated 2024 Monjuvi U.S. net product sales are expected to be in the range of US$ 80 to 95 million, with 2024 OpEx in the range of € 350 to 380 million and 2024 cash burn of approximately € 250 million. The company also reduced its financial liability from the collaboration with Incyte by approximately € 112 million. MorphoSys expects growth from new indications currently being investigated in Phase 3 studies. The company's CEO emphasized the potential of Monjuvi and the focus on maintaining a strong financial position in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
none
News

MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
MorphoSys AG (MOR) to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.66%
Tags
conferences
-
News

MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study

Rhea-AI Summary
MorphoSys AG (MOR) announced comprehensive results from the Phase 3 MANIFEST-2 study investigating pelabresib, an investigational BET inhibitor, in combination with the JAK inhibitor ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis. The study demonstrated significant reductions in spleen size and symptoms, improved measures of anemia, bone marrow fibrosis, and a well-tolerated safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.25%
Tags
clinical trial
-
News

MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction

Rhea-AI Summary
MorphoSys AG (MOR) announced strong topline results from the Phase 3 MANIFEST-2 study, showing pelabresib's significant improvement in myelofibrosis patients. The combination therapy met the primary endpoint, nearly doubling SVR35 response rate, and demonstrated meaningful anemia improvement. Key secondary endpoints assessing symptom reduction and TSS showed significant improvements for intermediate-risk patients. Safety results were consistent with prior clinical trials. MorphoSys intends to submit for approval in the U.S. and Europe in mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.35%
Tags
clinical trial
News

MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results

Rhea-AI Summary
MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports Q3 2023 results, including Monjuvi U.S. net product sales of US$ 23.4 million. Phase 3 MANIFEST-2 topline results expected by end of November, with detailed findings in oral presentation at ASH 2023. U.S. FDA granted Fast Track designation for tulmimetostat in ARID1A-mutated endometrial cancer. Company has € 642.2 million in cash and other financial assets as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.79%
Tags
earnings
-
News

Invitation to MorphoSys' Third Quarter and First Nine Months 2023 Financial Results Conference Call on November 16, 2023

Rhea-AI Summary
MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will release its Q3 and first nine months 2023 results on November 15, 2023, with a conference call and webcast on November 16, 2023. The Management team will present the results and outlook, followed by a Q&A session. Participants can join via phone or webcast, with a replay available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.06%
Tags
earnings
-
News

MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting

Rhea-AI Summary
MorphoSys AG announced that data from the Phase 3 MANIFEST-2 trial of pelabresib will be presented at the ASH Annual Meeting. The trial evaluated the investigational BET inhibitor in combination with the JAK inhibitor ruxolitinib in myelofibrosis patients. The company will also share topline results from the study in the coming weeks.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.39%
Tags
clinical trial
News

MorphoSys Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023

Rhea-AI Summary
MorphoSys reports preliminary Q3 2023 net product sales of $23.4 million for Monjuvi in the US. Full year 2023 sales expected to be $85-95 million with a gross margin of approximately 75%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.92%
Tags
earnings

FAQ

What is the current stock price of MorphoSys American Depositary Shares (MOR)?

The current stock price of MorphoSys American Depositary Shares (MOR) is $18.64 as of August 5, 2024.

What is the market cap of MorphoSys American Depositary Shares (MOR)?

The market cap of MorphoSys American Depositary Shares (MOR) is approximately 2.9B.

What is MorphoSys AG?

MorphoSys AG is a biopharmaceutical company focusing on developing therapies for cancer and autoimmune diseases. It is headquartered in Planegg, Germany, with a U.S. subsidiary in Boston.

What are MorphoSys' key products?

MorphoSys' key products include Tremfya (guselkumab) for plaque psoriasis and Monjuvi (tafasitamab-cxix) for certain types of lymphoma.

What is the financial performance of Monjuvi?

Monjuvi U.S. net product sales were $92 million for 2023 with a gross margin of 69%. The projected sales for 2024 range between $80 and $95 million.

What are the latest developments in MorphoSys' pipeline?

MorphoSys is investigating new indications for Monjuvi through Phase 3 trials and is preparing regulatory filings for pelabresib, an investigational treatment for myelofibrosis.

What is the significance of the Business Combination Agreement with Novartis?

The agreement includes Novartis' acquisition of MorphoSys and exclusive rights to develop and commercialize pelabresib and tulmimetostat. Additionally, MorphoSys will transfer tafasitamab rights to Incyte Corporation.

Where can I find more information about MorphoSys?

You can find more information on MorphoSys' official website at www.morphosys.com and follow them on Twitter and LinkedIn.

What is pelabresib?

Pelabresib is an investigational selective small molecule that inhibits bromodomain and extra-terminal domain (BET) proteins. It is being investigated for the treatment of myelofibrosis.

Who are MorphoSys' partners for their products?

MorphoSys partners include Janssen Biotech for Tremfya and Incyte Corporation for tafasitamab (marketed as Monjuvi in the U.S. and Minjuvi in Europe and Canada).

What is Monjuvi approved for?

Monjuvi (tafasitamab-cxix) is approved in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified.

What are MorphoSys' future plans?

MorphoSys aims to advance its clinical programs, optimize operating expenses, and prepare regulatory filings for new treatments, including pelabresib for myelofibrosis.

Stock MOR logo
MorphoSys AG American Depositary Shares

Nasdaq:MOR

MOR Rankings

#1694 Ranked by Market Cap
N/A Ranked by Dividends

MOR Stock Data

2.86B
150.65M
7.44%
0.09%
Biotechnology
Healthcare
Link
United States of America
Planegg